Lat­est news on J&J’s NSCLC ap­proval, Bris­tol My­ers Squibb’s big TIG­IT bet, #AS­CO21 and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Be sure to check out our 60 over 60 spe­cial — our way of hon­or­ing those who have left last­ing lega­cies in bio­phar­ma. We have al­ready re­ceived some thought­ful feed­back from read­ers, which we al­ways ap­pre­ci­ate. Aside from re­ply­ing to this email, we now have a Let­ter to Ed­i­tors sec­tion where you can reg­is­ter your opin­ion pub­licly.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER